Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of BI 754091 alone or with BI 836880 in unresectable chemotherapy-refractory metastatic anal squamous cell carcinoma
MOH_2020-09-06_009293Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anal squamous cell carcinoma (SCCA) comparing BI 754091 monotherapy with BI 754091 + BI 836880 (2 arms). Planned start Aug 2020; status: not yet recruiting.
02
Drugs
ezabenlimabBI 836880
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on MOH_2020-09-06_009293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-06_009293.